Are GSK’s legal troubles a threat to the firm’s survival?
Pharmaceutical giant GlaxoSmithKline is facing legal action over heartburn drug Zantac that has seen billions wiped off its market value. Rupert Hargreaves looks at how it might affect the business's prospects.
Over the past week, GSK (LSE: GSK) shares have fallen off a cliff. The FTSE 100 company has seen its market value plunge 17% and recent spin-off Haleon (LSE: HLN) has followed suit, plunging 14%.
We don’t have to look far to understand why investors have been running for the hills. It all comes back to a drug called Zantac, an over-the-counter heartburn drug that was pulled from sale in 2019.
A legacy drug comes back to haunt GSK
GSK launched Zantac in 1981 as a prescription medication and it went on to become an over-the-counter treatment in the mid-90s. Now there’s a bit of a corporate paper trail to get through here to explain what happened next.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The drug was developed in a joint venture with a company called Warner Lambert. Warner bought out its partner, GSK in 1998, but was then acquired by Pfizer (NYSE: PFE). Pfizer sold its over-the-counter business (including Zantac) to Boehringer, which then sold this business on to French pharmaceutical giant Sanofi.
As a result, all of these pharmaceutical companies have some exposure to the drug, and, therefore, they have exposure to a growing volume of lawsuits that argue the drug causes cancer. Litigants also argue that Sanofi, Pfizer and GSK all didn’t do enough to warn customers of the risks of taking Zantac.
Haleon, which is an amalgamation of both GSK’s and Pfizer’s over-the-counter and consumer healthcare businesses, is the most exposed of all.
Its IPO prospectus stated that GSK and Pfizer have been named as defendants in more than 2,000 US personal injury lawsuits involving Zantac. However, the group has stated that it has indemnification obligations with both companies and has never marketed Zantac in the US suggesting the risk goes back up the chain to GSK and Pfizer.
The problem with all of this is the fact that potential liabilities are impossible to estimate. The US legal system is notoriously complex and litigious. What’s more, courts have been awarding ever larger sums to successful litigants and juries are siding with clamints in a thinly veiled fightback against corporate greed.
Johnson & Johnson (NYSE: JNJ) is facing billions in liabilities as courts have ruled in favour of plaintiffs who claim the company’s talc-based baby powder can cause cancer.
Meanwhile, in June 2020 German pharmaceutical and life sciences giant Bayer agreed to pay $10.9bn to settle 95,000 cases against the group arguing that the herbicide, Roundup, caused cancer.
The size of the award is a threat to GSK shares
While there’s a risk GSK, Pfizer, Sanofi and even Haleon could end up facing one of these large judgments, there has been some good news this week.
The first Zantac case was slated to come to trial on August 22, but the plaintiff has now decided to file a Notice of Voluntary Dismissal. GSK claims that it has “not paid anything in exchange for the voluntary dismissal,” and the group believes this is the best outcome as the “overwhelming weight of the scientific evidence” supports the conclusion there is no increased cancer risk from the drug.
This suggests GSK and its peers might get off lightly, but I think it’s too soon for investors to breathe a sigh of relief. GSK has been named as a defendant in as many as 3,000 personal injury cases filed in federal and state courts. With these numbers one thing’s for sure, the pharmaceutical giants face a long, expensive legal battle as they work through the outstanding cases. And if just one case gets through, it could set off another wave of litigation.
So it’s not really surprising that investors have hit the sell button first and are waiting to ask questions later. All of these companies are facing potentially billions of dollars of legal expenses in the best case, and even larger sums of money in the worst case scenario.
Still, I think it’s unlikely these legal wrangles will lead to either company’s demise. Lawsuits are just part of doing business in the US, and both firms will have plans in place to deal with the threat. All the stakeholders also have an interest in agreeing to a deal that both meets claimants’ demands and allows the organisations to continue functioning. Insolvent businesses won’t be any use to anyone.
Growth might suffer as the companies divert cash to fund their legal battles, but it seems unlikely the fallout will be terminal.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Rupert is the former deputy digital editor of MoneyWeek. He's an active investor and has always been fascinated by the world of business and investing. His style has been heavily influenced by US investors Warren Buffett and Philip Carret. He is always looking for high-quality growth opportunities trading at a reasonable price, preferring cash generative businesses with strong balance sheets over blue-sky growth stocks.
Rupert has written for many UK and international publications including the Motley Fool, Gurufocus and ValueWalk, aimed at a range of readers; from the first timers to experienced high-net-worth individuals. Rupert has also founded and managed several businesses, including the New York-based hedge fund newsletter, Hidden Value Stocks. He has written over 20 ebooks and appeared as an expert commentator on the BBC World Service.
-
Invest in Grainger: a landlord with growth potential
Grainger is putting years of uncertainty behind it and investing for expansion
By Rupert Hargreaves Published
-
Zoopla: could a good local pub increase your house price?
Research from Zoopla shows that the local pub influenced a quarter of homeowners’ decision to buy. Could your local pub increase your house price?
By Dan McEvoy Published
-
Halifax: House price slump continues as prices slide for the sixth consecutive month
UK house prices fell again in September as buyers returned, but the slowdown was not as fast as anticipated, latest Halifax data shows. Where are house prices falling the most?
By Kalpana Fitzpatrick Published
-
Rents hit a record high - but is the opportunity for buy-to-let investors still strong?
UK rent prices have hit a record high with the average hitting over £1,200 a month says Rightmove. Are there still opportunities in buy-to-let?
By Marc Shoffman Published
-
Pension savers turn to gold investments
Investors are racing to buy gold to protect their pensions from a stock market correction and high inflation, experts say
By Ruth Emery Published
-
Where to find the best returns from student accommodation
Student accommodation can be a lucrative investment if you know where to look.
By Marc Shoffman Published
-
Best investing apps
Looking for an easy-to-use app to help you start investing, keep track of your portfolio or make trades on the go? We round up the best investing apps
By Ruth Emery Last updated
-
The world’s best bargain stocks
Searching for bargain stocks with Alec Cutler of the Orbis Global Balanced Fund, who tells Andrew Van Sickle which sectors are being overlooked.
By Andrew Van Sickle Published
-
Revealed: the cheapest cities to own a home in Britain
New research reveals the cheapest cities to own a home, taking account of mortgage payments, utility bills and council tax
By Ruth Emery Published
-
UK recession: How to protect your portfolio
As the UK recession is confirmed, we look at ways to protect your wealth.
By Henry Sandercock Last updated